Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
about
Rational polynomial representation of ribonucleotide reductase activityTwo proteins mediate class II ribonucleotide reductase activity in Pseudomonas aeruginosa: expression and transcriptional analysis of the aerobic enzymesChemical dissection of the cell cycle: probes for cell biology and anti-cancer drug development.Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9Phenyl-1-Pyridin-2yl-ethanone-based iron chelators increase IκB-α expression, modulate CDK2 and CDK9 activities, and inhibit HIV-1 transcriptionEssential thrombocythemia (ET): moving from palliation to cure.Antitumor activity of sugar-modified cytosine nucleosides.Ribonucleotide reductase inhibitors: a new look at an old target for radiosensitization.RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).Targeting cancer by binding iron: Dissecting cellular signaling pathwaysRole of cellular iron and oxygen in the regulation of HIV-1 infection.Targeting ribonucleotide reductase for cancer therapy.Protein Phosphatase-1 -targeted Small Molecules, Iron Chelators and Curcumin Analogs as HIV-1 Antivirals.E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.Crosstalk between the Smad and the Mitogen-Activated Protein Kinase Pathways is Essential for Erythroid Differentiation of Erythroleukemia Cells Induced by TGF-β, Activin, Hydroxyurea and ButyrateNovel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents.QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target predictionQSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors
P2860
Q24810157-00C4759A-22F1-44A4-8CEF-F1665C7E99DEQ28492748-0A4C1920-167C-4E3A-926E-1EAA62356D88Q30599549-983FB16C-2FB0-4358-A38C-10089B55184AQ34458484-38536CE8-7FF3-4DE6-A757-40E9166B6E6CQ34596398-1B3DAC3D-C775-4782-9081-78CAEBE4510DQ35022117-C31BE273-5253-4780-8FAE-59691FE6BCA5Q35668415-91A025F6-0DB9-4EF9-ADF2-9EFEF9246777Q35971759-290069DB-8EBE-4688-9914-79AC1319C7C3Q36015018-07DECD35-F95E-4129-82FD-1D1B55981AC3Q36041069-1CDD0A26-D989-4AE2-9E82-1FED633C4E63Q36326247-89A89111-B78B-49B6-BE36-9DD56178226CQ36839068-906BA8EF-07D6-408E-8BBD-1E61FF5743E1Q38148222-903CC7B8-37B0-477A-A658-0F84A59B3540Q38662748-57B820C1-A47E-4D69-9D19-A3A21D42BED3Q39827602-65BFF7B0-3F2D-4819-B6A8-E1F8D8DEDB8EQ41953092-DE691518-08A6-42DA-9BC0-5B5598D4DA08Q44517505-6410EA92-7588-4164-A19A-07C359AAC53CQ57991024-414EA48D-BC67-4490-8A30-4469E8416251Q57991027-A637B877-0FEB-41B7-8F60-6510B698ED19
P2860
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@ast
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@en
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@nl
type
label
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@ast
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@en
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@nl
prefLabel
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@ast
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@en
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@nl
P2860
P356
P1476
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
@en
P2093
Francis J Giles
Yesid Alvarado
P2860
P304
P356
10.1586/14737140.2.4.437
P577
2002-08-01T00:00:00Z